Previous 10 | Next 10 |
2023-05-16 05:41:00 ET So far, 2023 is turning out to be a pretty good year for growth stock investors in general. The Vanguard Growth ETF has already gained 19% in 2023. For investors with either CRISPR Therapeutics (NASDAQ: CRSP) or Nanox (NASDAQ: NNOX) in their po...
2023-05-15 13:48:03 ET CRISPR Therapeutics AG (CRSP) JMP Securities Life Sciences Conference May 15, 2023 11:30 AM ET Company Participants Sam Kulkarni - CEO Conference Call Participants Silvan Türkcan - JMP Securities Presentation Silvan T...
2023-05-15 13:44:44 ET Shares of the SPDR S&P Biotech ETF ( NYSEARCA: XBI ) moved up to a new 3-month trading high on Monday afternoon as the exchange traded fund picked up 3.5% on the day. Moreover, the fund opened trading at $85.72 a share and moved up to $88.20 a...
2023-05-11 15:13:59 ET Despite another less-than-stellar Consumer Price Index report and more volatility among regional bank stocks, growth equities, on balance, were on the upswing this week. The tech-heavy Nasdaq Composite , for instance, edged higher by nearly 3% during the first thr...
2023-05-09 14:25:44 ET Shares of the developmental gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) were up by 12.4% on sky-high volume as of 1:46 p.m. ET Tuesday afternoon. The big gain came in response to the biotech 's strong 2023 first-quarter financial results, which...
2023-05-09 14:02:02 ET Shares of CRISPR Therapeutics ( NASDAQ: CRSP ) gained ~13% on Tuesday to reach the highest level since October after the gene-editing company announced its Q1 2023 results along with an update on its clinical pipeline. The Swiss biotech reported $100M ...
2023-05-08 16:38:55 ET CRISPR Therapeutics press release ( NASDAQ: CRSP ): Q1 GAAP EPS of -$0.67 beats by $0.97 . Revenue of $100M beats by $75.67M . Collaboration revenue recognized in the first quarter of 2023 was primarily attributable to revenue recognized ...
-Regulatory submissions complete for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, in the U.S. for transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD)- -EU and U.K. submissions validated by European Medicines Agency (EMA) and the Med...
2023-05-04 15:36:19 ET Despite a YTD gain of ~21% in its shares, Piper Sandler analyst Christopher Raymond assumed coverage of Vertex Pharmaceuticals ( NASDAQ: VRTX ) with an Overweight rating and a $385 per share target on Thursday, noting further upside from the company’...
2023-05-04 10:38:25 ET Growth stocks have performed surprisingly well in 2023. Despite ever-rising interest rates, a possible recession, and a regional banking crisis, the growth-oriented Nasdaq Composite has ticked higher by an impressive 14.8% so far this year. Which growth st...
News, Short Squeeze, Breakout and More Instantly...
CRISPR Therapeutics AG Company Name:
CRSP Stock Symbol:
NASDAQ Market:
CRISPR Therapeutics AG Website: